For the quarter ending 2026-03-31, ENTA made $17,159K in revenue. -$13,091K in net income. Net profit margin of -76.29%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total revenue | 17,159 | 18,615 | 15,464* | 18,314 |
| Research and development | 19,443 | 20,859 | 23,827* | 27,210 |
| General and administrative | 9,568 | 9,009 | 11,856* | 9,997 |
| Total operating expenses | 29,011 | 29,868 | 35,682* | 37,207 |
| Loss from operations | -11,852 | -11,253 | -20,218* | -18,893 |
| Interest expense | 3,316 | 3,083 | 2,653* | 1,618 |
| Interest and investment income, net | 2,084 | 2,422 | 2,577* | 2,285 |
| Change in fair value of series 1 nonconvertible preferred stock | - | - | 10* | - |
| Total other (expense) income, net | -1,232 | -661 | -67* | 667 |
| Loss before income taxes | -13,084 | -11,914 | -20,286* | -18,226 |
| Income tax (expense) benefit | 7 | 24 | 254* | 29 |
| Net loss | -13,091 | -11,938 | -20,540 | -18,255 |
| Basic EPS | -0.45 | -0.42 | 0.481 | -0.85 |
| Diluted EPS | -0.45 | -0.42 | 0.481 | -0.85 |
| Basic Average Shares | 29,040,000 | 28,748,000 | -42,667,992 | 21,377,000 |
| Diluted Average Shares | 29,040,000 | 28,748,000 | -42,667,992 | 21,377,000 |
ENANTA PHARMACEUTICALS INC (ENTA)
ENANTA PHARMACEUTICALS INC (ENTA)